Royce & Associates LP Has $6.88 Million Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Royce & Associates LP lessened its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 56.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 312,184 shares of the company’s stock after selling 398,303 shares during the period. Royce & Associates LP’s holdings in Cellebrite DI were worth $6,877,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC lifted its holdings in Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock worth $94,586,000 after purchasing an additional 3,239,307 shares during the last quarter. True Wind Capital Management L.P. increased its position in Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock worth $305,358,000 after buying an additional 2,130,386 shares during the period. Principal Financial Group Inc. acquired a new stake in shares of Cellebrite DI during the third quarter worth $23,402,000. Lord Abbett & CO. LLC bought a new stake in shares of Cellebrite DI in the third quarter valued at about $11,523,000. Finally, Summit Partners Public Asset Management LLC acquired a new position in shares of Cellebrite DI in the third quarter valued at about $9,274,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CLBT. Lake Street Capital lifted their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of Cellebrite DI in a research report on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $23.43.

Cellebrite DI Trading Down 0.8 %

CLBT stock opened at $18.52 on Wednesday. The firm has a 50-day moving average price of $21.27 and a 200-day moving average price of $19.75. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30. The stock has a market capitalization of $3.81 billion, a P/E ratio of -13.32, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, equities analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.